September 20, 2025 a 08:00 am
TECH: Fundamental Ratio Analysis - Bio-Techne Corporation
Bio-Techne Corporation operates in a dynamic biotech market, offering a range of life science reagents, instruments, and services. With a solid portfolio in Protein Sciences and Diagnostics and Genomics, the company is positioned well for growth. However, careful monitoring of financial metrics and market competition is essential.
Fundamental Rating
Bio-Techne Corporation has a fundamental rating of 'B', indicating a stable financial position. The scores reflect moderate performance across financial metrics.
| Category | Score | Visualization |
|---|---|---|
| Discounted Cash Flow | 4/5 | |
| Return on Equity | 3/5 | |
| Return on Assets | 4/5 | |
| Debt to Equity | 2/5 | |
| Price to Earnings | 1/5 | |
| Price to Book | 2/5 |
Historical Rating
Reviewing historical scores helps in understanding the company's performance trend over time.
| Date | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2025-09-19 | 3 | 4 | 3 | 4 | 2 | 1 | 2 |
| Previous | 0 | 4 | 3 | 4 | 2 | 1 | 2 |
Analyst Price Targets
Analyst price targets provide insight into potential stock performance, based on projections and market analysis.
| High | Low | Median | Consensus |
|---|---|---|---|
| 73 | 73 | 73 | 73 |
Analyst Sentiment
The consensus rating suggests confidence in the stock, with the majority of analysts recommending a 'Buy'.
| Recommendation | Count | Visualization |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 16 | |
| Hold | 7 | |
| Sell | 0 | |
| Strong Sell | 0 |
Conclusion
Bio-Techne Corporation showcases strong potential in the biotechnology sector, supported by a diverse product portfolio and robust research capabilities. While its financials indicate solid performance, attention to P/E and debt ratios is warranted. The analyst consensus is optimistic, but market volatility and competitive pressures should be monitored. Overall, investors may find this stock an attractive option with some due diligence.